Founded in 1987, Cephalon, Inc. develops and markets innovative
products to treat sleep and neurological disorders, cancer, pain
and addiction, with annual revenues exceeding $1 billion. Cephalon
employs approximately 3,000 people in the United States and Europe.
It markets PROVIGI
...
L(r) (modafinil) [C-IV], GABITRIL(r) (tiagabine hydrochloride)
ACTIQ(r) (oral transmucosal fentanyl citrate) [C-II], TRISENOX(r)
(arsenic trioxide) injection, VIVITROL(r) (naltrexone for
extended-release injectable suspension) in the U.S. and numerous
products internationally.
